Illumina

Illumina is redefining whole-genome sequencing, bringing the accuracy and ease of short-read sequencing to comprehensive, genome-wide insight.   Running on the NovaSeq X with no additional equipment required, TruPath™ expands access to whole-genome sequencing and reveals historically dark regions of the genome for innovators around the world.   Learn more 🔗 : https://lnkd.in/g5eUT56H

When the challenge is clinical adoption of genomics 🧬 — who you gonna call? Illumina Medical Affairs! Meet our US-Canada team supporting reproductive health and genetic disease testing. From publishing research that informs payer guidelines, to educating healthcare providers, to helping laboratories make the clinical and economic case for genomic testing, this crew plays a critical role. 🔗 Read our spotlight on this team and how they’re working behind the scenes to bring genomics into mainstream care: https://lnkd.in/gWQgauaB

Ovarian cancer is notoriously difficult to catch early — with a diagnostic journey that can be invasive and imprecise. Bodour Salhia, Ph.D, Professor of Cancer Biology at the Keck School of Medicine of the University of Southern California is using multiomics to advance early detection by improving the ability to distinguish between cancerous and non-cancerous tumors. In a research study she used Illumina Connected Multiomics to interrogate methylation, protein, and spatial data — improving tumor classification and revealing insights traditional methods may miss. ➡️ Read the full feature to learn how Illumina’s integrated technology is advancing research into new screening tools for ovarian cancer: https://lnkd.in/eh4-ZQZh

Bloomberg featured CEO Jacob Thaysen to discuss the company’s Q1 earnings report and confidence in continued growth ahead. “We see a lot of strength in the clinical space, and particularly in oncology.” As Illumina continues its strategy, we’re focused on supporting clinical stakeholders to get the right treatment at the right time to more cancer patients. Watch the full interview on Bloomberg: https://lnkd.in/gcP7HZbH

In the first quarter of 2026, we accelerated our strategy across AI insights, genomic and multiomic innovation, and clinical strength. Here are the highlights 👇    🔶 Unlocking speed and scale for drug discovery: We introduced the Billion Cell Atlas, the most comprehensive map of human disease biology to help train the next generation of AI models for drug target identification.    🔶 Driving the insight ecosystem: With the launch of TruPath™ Genome we delivered the simplest workflow for comprehensive whole-genome variant detection. We also unveiled a roadmap of NovaSeq™ X advancements including Q70 accuracy + 35B flow cells, and our customers shared new data that illustrates the impact of our multiomics portfolio.     🔶 Strengthening customer access to proteomic insights at scale: We officially welcomed the SomaLogic team to Illumina, helping customers generate rich multiomic datasets in support of better outcomes for patients.     🔶 Advancing our global clinical strategy: Dr. Eric Green joined Illumina as Chief Medical Officer to help advance the clinical use of genomics, expand access to precision medicine solutions, and increase the diversity of genomics data. Learn more at https://www.illumina.com/

What does it take to power the next wave of AI-driven drug discovery? Biological data—at an entirely new scale. The Billion Cell Atlas is designed to deliver just that: a first-of-its-kind resource built to train AI models for precision medicine and drug target identification. Hear directly from Kyle Kai-How Farh MD PhD , VP & Distinguished Scientist at Illumina, and explore the full story: https://lnkd.in/guhpN4nz

🎥 In celebration of #DNADay, Illumina employees around the world went back to the classroom to show students how genomics can help address global challenges. 🧬 Through hands‑on science and career conversations, employees connected thousands of learners with the people behind the science—helping make careers in genomics feel more personal and possible. What made this campaign especially meaningful was the collective participation: educators welcomed volunteers into their learning spaces, and students showed up with curiosity, enthusiasm, and excitement about what a future in STEM could look like. The future is bright indeed, and we can’t wait to see how the STEM leaders of tomorrow help expand access to genomic breakthroughs around the world. Happy DNA Day! Learn more at: dnaday.org

🎥 Just how easy is TruPath™ Genome? We sent Illumina’s Chief Medical Officer Eric Green, M.D., Ph.D. back to the bench to try it for himself. At Illumina Lab Services, Dr. Green rose to the challenge—sharing a few laughs along the way—to demonstrate the unprecedented simplicity of a product that unlocks a whole new standard for genomic insights. Learn more about TruPath™ Genome: https://lnkd.in/g5eUT56H

Pushing the boundaries of cancer research, one discovery at a time. We recently attended #AACR26, where we showcased our latest advancements in single-cell, spatial, and multiomics technologies and how they’re accelerating translational research and drug discovery. Insights from leaders like Richard Capper, Stewart Comer, Jing Gao, Severine Catreux, Kyle Kai-How Farh MD PhD, Bodour Salhia, Ph.D, David Spencer, and Claire Mills, DDS highlighted how we’re scaling multiomics for deeper biological understanding and enabling the next wave of breakthroughs in cancer research. As we look ahead, we're focused on advancing scalable, integrated solutions that empower researchers to translate complex biology into life-saving impact.

At #AACR26, Illumina customers continued asking bolder, more complex scientific questions—so we're launching a new research grant to fuel that creativity and spotlight methylation 🧬 Our 5-Base Solution for Cancer Research Grant Contest promotes epigenetic research in oncology by providing access to Illumina’s integrated dualomic solution, 5-Base. The grant winner will receive Illumina 5-Base DNA Prep or Illumina 5-Base DNA Prep with Enrichment kits and core consumables to cover 1000 samples in pursuit of their research project. Learn more about eligibility and apply now—grant project proposals will be reviewed through June 26 🗓️ : https://lnkd.in/dWeCwKF2